Clinical Trials Browser

Triple Negative Breast Neoplasms

Esophageal Neoplasms

Locally Advanced Rectal Cancer

Rectal Cancer Patients

Salivary Gland Neoplasms

Esophageal Squamous Cell Carcinoma

Stomach Neoplasms

Triple Negative Breast Neoplasms

Advanced Biliary Tract Carcinoma

Squamous Cell Carcinoma of Head and Neck, Laryngeal Neoplasms, Mouth Neoplasms

Colorectal Neoplasms

Gestational Trophoblastic Disease

Adenocarcinoma

Carcinoma, Hepatocellular

Nasopharyngeal Carcinoma

Carcinoma, Hepatocellular

Esophageal Squamous Cell Carcinoma

Endometrioid Endometrial Cancer

Carcinoma, Hepatocellular

Cervical Cancer Metastatic

Esophageal Neoplasms

Esophageal Squamour Cell Cancer

Biliary Tract Neoplasms

Breast Neoplasms, Triple Negative Breast Neoplasms

Carcinoma, Hepatocellular

Liver Neoplasms

Breast Neoplasms

Locally Advanced Rectal Cancer

Pancreatic Neoplasms

Squamous Cell Carcinoma of Head and Neck

Colonic Neoplasms

Adrenal Gland Neoplasms, Adrenocortical Carcinoma

Advanced Gastric Cancer

Gallbladder Neoplasms, Cholangiocarcinoma

Breast Neoplasms

Uterine Cervical Neoplasms

Stomach Neoplasms

Cholangiocarcinoma

Advanced Triple Negative Breast Cancer

Cholangiocarcinoma

Squamous Cell Carcinoma of Head and Neck

Pancreatic Neoplasms

Stomach Neoplasms

BRCA-Mutated Breast Carcinoma

Breast Neoplasms, Triple Negative Breast Neoplasms

Gastric Cancer Adenocarcinoma Metastatic

Liposarcoma, Sarcoma

Carcinoma, Hepatocellular

Clinical Trials

FUSCC Refractory TNBC Platform Study (FUTURE2.0)

STELLAR01

A Single-arm Phase II Clinical Study of Camrelizumab Combined With Long-course Chemoradiotherapy for Total Neoadjuvant Therapy in Locally Advanced Low pMMR/MSS Rectal Cancer

Short-Course Radiotherapy, Nal-IRI, Capecitabine, and Camrelizumab for Locally Advanced MSS Rectal Cancer

Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing

Camrelizumab, Chemotherapy and Ivarmacitinib in Patients With Resectable Esophageal Squamous Cell Carcinoma

Carilizumab and Albumin Paclitaxel for Second-line Treatment of Advanced Gastric Cancer

Camrelizumab Plus Risedronate and Chemotherapy for Triple-Negative Breast Cancer: An Exploratory Clinical Study on Mechanisms and Efficacy

Camrelizumab Plus Apatinib in Combination With GEMOX (Gemcitabine and Oxaliplatin ) in Patients With Locally Advanced Biliary Tract Cancer

NeoCamre-HN

A Clinical Study on the Treatment of Metastatic Colorectal Cancer at the Second-line or Beyond.

Camrelizumab Plus Apatinib in Patients With High-risk Gestational Trophoblastic Neoplasia

Camrelizumab Combined With or Without Apatinib and SOX of Neoadjuvant Treatment for Gastric Cancer

FAD-HCC-001

SBRT Combined With PD-1 Antibody and Chemotherapy in Oligometastatic Nasopharyngeal Carcinoma

Ivarmacitinib Combined With Camrelizumab and Apatinib for Unresectable Advanced Hepatocellular Carcinoma With Acquired Resistance to Immune Checkpoint Therapy: A Single-Arm Exploratory Clinical Study

Nimotuzumab,Camrelizumab, and Neoadjuvant Chemotherapy（nCT） in the Treatment of Esophageal Squamous Cell Carcinoma

Clinical Efficacy Study of PD-1 Inhibitor Combined With Neoadjuvant Chemotherapy in Advanced Endometrial Cancer

ICIs and Anti-VEGF Antibody/TKIs With or Without Interventional Therapy for Advanced HCC

A Prospective, Randomized, Parallel Trial of Famitinib Malate at Different Doses Combined With Camrelizumab for the Treatment of Recurrent and Metastatic Cervical Cancer

A Multicenter Phase II Clinical Study of Neoadjuvant Use of Camrelizumab in Combination With Chemotherapy for Organ Preservation in Esophageal Cancer

Neoadjuvant Camrelizumab With Palbociclib for Resectable Esophageal Squamous Cell Carcinoma

Disitamab Vedotin Plus Lenvatinib and PD-1 Inhibitors for Treating HER2-positive Advanced Biliary Tract Cancer

FASCINATE-N

LEAF-02

TASK-05

Camella

Involved-field Radiotherapy-TNT Combined With PD-1 Inhibitor for pMMR Locally Advanced Rectal Cancer (Neo-Field I)

PTCA199-8

Camrelizumab in Combination With Chemotherapy or Apatinib Mesylate as First-Line Treatment for R/M HNSCC

Neoadjuvant Therapy for Locally Advanced Colon Cancer

Phase II Study of PD-1 Inhibitor Combined With Apatinib and Mitotane in the Treatment of Advanced Adrenal Cortical Carcinoma

Camrelizumab Combined with Apatinib Mesylate Tablets, Nab-paclitaxel and S-1 in the Treatment of Locally Advanced Gastric Cancer

Camrelizumab and Chemotherapy With or Without Anlotinib as First-line Treatment for Advanced Gallbladder Cancer and Extrahepatic Cholangiocarcinoma

A Trial of Camrelizumab Plus Nab-paclitaxel and Levocetirizine in Metastatic or Recurrent TNBC

Neoadjuvant Immunochemotherapy in PD-L1-negative LACC

Conversion Effects of PD-1 Antibody Camrelizumab Combined With Nab-POF Regimen Chemotherpy in Patients With Initially Unresectable Locally Advanced or Limited Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma：FDZL-GC001 Trial

Camrelizumab Plus Apatinib and Temozolomide as Neoadjuvant in High Risk Acral Melanoma

Cryoablation Combined with Anti-PD-1 Antibody in Patients with Advanced Intrahepatic Cholangiocarcinoma

SHIFT-001

CCGLC-005

NEOPBOSCC

Metronomic Capecitabine with Camrelizumab and Apatinib Mesylate for Treatment of Advanced Pancreatic Cancer

Neoadjuvant Immunotherapy for Resectable Gastric Cancer

Neoadjuvant Treatment of gBRCA-Mutated HER2-Negative Breast Cancer With HRS-1167 and Famitinib ± Camrelizumab

JAK1 Inhibitor Ivarmacitinib Reversing Immunotherapy Resistance in TNBC

Trifluridine/tipiracil (TAS-102), Bevacizumab, and Camrelizumab As Third-line or Later-line Therapy of Gastric Cancer

First-line Treatment of Advanced/unresectable DDLPS

SPRING

Hepatic Arterial Infusion Combined With Lenvatinib and Camrelizumab for Unresectable Hepatocellular Carcinoma